Alan Jenks’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (2)


Figure 1: Overview of mRNA-LNP vaccine components.
Summary of human trials of non-covid-19 coronavirus vaccines. Adapted from [100]
The Novelty of mRNA Vaccines and Potential Harms: A Scoping Review
  • Preprint
  • File available

January 2023

·

356 Reads

·

1 Citation

·

·

Alan Jenks

·

Theresa Lawrie

Pharmacovigilance databases are showing evidence of injury in the context of the COVID-19 modified mRNA shots. According to recent publications, adverse event reports linked to the mRNA COVID-19 products largely point to the spike protein as an aetiological agent of adverse events, but we propose that the platform itself may be culpable. To assess the safety of current and future mRNA vaccines, further analysis on the risks due to the platform itself, and not specifically the expressed antigen. If harm can be exclusively and conclusively attributed to the spike protein, then it is possible that future mRNA vaccines expressing other antigens will be safe. If harms are attributable to the platform itself, then regardless of the toxicity, or lack thereof, of the chosen payload therein, the platform may be inherently unsafe, pending modification. In this work, we examine previous studies of RNA-based delivery by a lipid nanoparticle and break down the possible etiological elements of harm.

Download

Summary of human trials of non-covid-19 coronavirus vaccines. Adapted from [67]
The Novelty of mRNA Vaccines and Potential Harms: A Scoping Review

January 2023

·

208 Reads

·

2 Citations

Pharmacovigilance databases are showing evidence of injury in the context of the COVID-19 modified mRNA shots. According to recent publications, adverse event reports linked to the mRNA COVID-19 products largely point to the spike protein as an aetiological agent of adverse events, but we propose that the platform itself may be culpable. To assess the safety of current and future mRNA vaccines, further analysis on the risks due to the platform itself, and not specifically the expressed antigen. If harm can be exclusively and conclusively attributed to the spike protein, then it is possible that future mRNA vaccines expressing other antigens will be safe. If harms are attributable to the platform itself, then regardless of the toxicity, or lack thereof, of the chosen payload therein, the platform may be inherently unsafe, pending modification. In this work, we examine previous studies of RNA-based delivery by a lipid nanoparticle and break down the possible etiological elements of harm.

Citations (2)


... The vaccines most commonly administered were Comirnaty (Pfizer/BioN-Tech), Covishield (Astrazeneca), CoronaVac (Sinovac), Spikevax (Moderna), Jcovden (Johnson & Johnson) 2 . Of these, approximately 30% of the doses produced by January 22, 2022 were in the form of a novel vaccine with a synthetic N1-methyl-pseudoiridinylated mRNA encapsulated in a lipid nanoparticle (LNP) 3 . ...

Reference:

Strategies for the Management of Spike Protein-Related Pathology
The Novelty of mRNA Vaccines and Potential Harms: A Scoping Review

... The potential toxicity of LNP components has been reviewed recently (48) and was already anticipated in the above mentioned 2016 paper from Langer's group: (49) "Among the most problematic are the potential toxicity of LNP components, including cationic lipids, phospholipids or combinations thereof. The immunogenicity of PEG and the decreased interaction of the LNPs with the endosomal membranes that hinders endosomal escape are also important issues for both siRNA and mRNA delivery." ...

The Novelty of mRNA Vaccines and Potential Harms: A Scoping Review